[1] 宫跃敏, 马永超, 陈小玉,等. 抗人 T 细胞猪免疫球蛋白联合艾曲泊帕治疗初发重型再生障碍性贫血疗效分析[J]. 临床血液学杂志, 2023, 36: 482-487. [2] Yang W, Liu X, Zhao X, et al. Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospec-tive study[J].Ther Adv Hematol, 2023, 14: 20406207221146031.doi:10.1177/20406207221146031. [3] Peffault De Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia[J].N Engl J Med,2022,386:11-23.doi:10.1056/NEJMoa2109965. [4] Patel BA, Ghannam J, Groarke EM, et al. Detectable mutations precede late myeloid neoplasia in aplastic anemia[J]. Haematologica, 2021, 106: 647. doi:10.3324/haematol.2020.263046. [5] 杨晗春, 成斐, 黄娟娟. 艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响(英文)[J]. 中国药学(英文版), 2023, 32: 736-743. [6] 焦雯静, 刘立民, 周惠芬,等. 艾曲波帕联合环孢素A治疗重型再生障碍性贫血疗效及安全性观察[J]. 中国实用内科杂志, 2022, 42: 573-576. [7] Wan Z, Chen Y, Zhuang J, et al. Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers[J]. Chin Med J (Engl), 2023, 136: 1120-1122. [8] Zhang XT, Zhang YN, Zhu JJ, et al. The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a Meta-analysis of randomized controlled trials[J]. Hematology, 2022, 27: 733-741. [9] Groarke EM, Patel BA, Shalhoub R, et al. Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia[J]. Leukemia, 2022, 36: 2328-2337. [10] 张慧敏, 袁丽倩, 史奎竹,等. 雄激素对再生障碍性贫血患者端粒长度影响的研究[J]. 河北医科大学学报, 2020, 41: 54-57. [11] 陈苗, 庄俊玲, 杨辰,等. 重型/极重型再生障碍性贫血患者免疫抑制治疗后早期死亡的临床特征及预测模型构建[J]. 中国实验血液学杂志, 2022, 43: 916-920. [12] Devillier R, Eikema DJ, Dufour C, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT[J]. Haematologica, 2023, 108: 2305.doi:10.3324/haematol.2022.281876. [13] Lu Y, Xiong M, Sun RJ, et al. Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study[J]. Leukemia Lymphoma, 2022, 63: 3307-3316. [14] 张樱, 张桂新, 庞爱明,等. 单倍体造血干细胞移植治疗重型再生障碍性贫血 76 例疗效分析[J].中华血液学杂志, 2023, 44: 202-210. [15] 宋娜, 孙鸣, 祁闪闪,等. 儿童异基因造血干细胞移植后细胞免疫重建的临床研究[J]. 临床儿科杂志, 2022, 40: 388-394. [16] 杜志丛, 赵艳丽, 曹星玉,等. 单倍型供者造血干细胞移植治疗重型再生障碍性贫血的单中心研究[J]. 临床血液学杂志, 2023, 36: 366-372. [17] Dezern AE, Brodsky RA. Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases[J]. Blood Rev, 2022: 101016. doi:10.1016/j.blre.2022.101016. [18] Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant[J]. J Hematol Oncol, 2017, 10: 1-10. doi:10.1186/s13045-017-0398-y [19] Xu LP, Wang SQ, Wu DP, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study[J]. Br J Haematol, 2016, 175: 265-274. [20] Tong L, Zhang L, Meng Y, et al. Analysis of children infected with varicella-zoster virus after hematopietic steam cell transplantation[J].中华血液学杂志, 2022, 43: 427-430. [21] Shi X, Liu X, Tang Y, et al. Autologous hematopoietic recovery after allogeneic hematopoietic stem cell transplantation: a case-based review[J].Transpl Immunol, 2023: 101920. doi:10.1016/j.trim.2023.101920. [22] Peffault De Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study[J] Am Soc Hematol, 2018, 132: 750-754. [23] Childs RW, Tian X, Vo P, et al. Combined haploiden-tical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome[J]. Br J Haeinatol,2021, 193: 951-960. |